DEF: Nuwellis Schedules 2026 Annual Meeting, Proposes Director Elections

Nuwellis, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for April 28, 2026, to elect two Class I directors and ratify the appointment of its independent auditor.

Summary

• Nuwellis, Inc. is holding its 2026 Annual Meeting of Stockholders virtually on April 28, 2026.
• The meeting agenda includes the election of two Class I directors for three-year terms and the ratification of Baker Tilly US, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
• Stockholders of record as of March 24, 2026, are entitled to vote.
• The Board of Directors recommends voting FOR the director nominees and FOR the ratification of the auditor.
• Proxy materials were first mailed to stockholders on or about April 2, 2026.
• The company has outlined procedures for virtual attendance, voting, and proxy submission via mail, internet, or phone.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it is a standard proxy statement for an annual meeting with routine proposals and no significant new financial or strategic information.

Positives

• The company is holding its annual meeting to ensure shareholder engagement and governance.
• The proposed director nominees have extensive experience in the medical device and financial sectors.
• The company has a clear process for stockholder communication with the Board.
• The Board of Directors is actively involved in risk oversight through its committees.
• An updated Insider Trading Compliance Policy was adopted to prevent insider trading and promote compliance.

Negatives

• The company experienced a net loss in 2025 ($17,521,000) and 2024 ($11,165,000).
• Net sales experienced a decline in 2024 (-1.4%) and 2025 (-5.4%).
• No cash bonuses were paid to named executive officers in 2024 for performance in fiscal year 2023.
• The company's Total Shareholder Return (TSR) has decreased significantly from $0.47 in 2023 to $0.03 in 2024 and $0.17 in 2025.

Risks

• The company's financial performance, including net losses and declining net sales, presents ongoing financial risk.
• The company's reliance on capital markets for funding may be impacted by current market conditions.
• Potential conflicts of interest in related party transactions are managed through the Audit Committee's review process.

Future Outlook

The filing does not contain specific forward-looking financial guidance. However, it details the upcoming annual meeting agenda, director nominations, and auditor ratification, indicating ongoing operational and governance activities.

Management Comments

• John L. Erb, President, Chief Executive Officer, and Chairman of the Board, expresses gratitude for continued support.
• The Board believes a virtual meeting provides greater access to stockholders.
• The Board recommends voting FOR each director nominee and FOR the ratification of Baker Tilly US, LLP.
• The Nominating and Corporate Governance Committee seeks directors with the highest ethical character, integrity, shared values, relevant expertise, sound business judgment, and commitment.
• The Board believes combining the CEO and Chair roles is currently in the best interest of the Company and its stockholders due to recent management changes.

Industry Context

StockSavvy.ai notes that Nuwellis, Inc. operates in the medical technology sector, focusing on cardiorenal conditions. The company's governance and director nominations align with standard practices for publicly traded companies in this industry, emphasizing experience in medical devices, finance, and leadership.

Management Changes

Corporate Governance

Related Party Transactions

• The Company engaged in no related party transactions required to be reported under Item 404 of Regulation S-K for the fiscal years ended December 31, 2025 and 2024.

Stakeholder Impact

• Shareholders: The election of directors and ratification of the auditor directly impact corporate governance and oversight. Stockholder proposals for future meetings are outlined.
• Management and Employees: Compensation structures, including base salaries, bonuses, and equity awards, are detailed, with recent adjustments made in 2024 to reduce cash burn.
• Independent Registered Public Accounting Firm: Baker Tilly US, LLP is proposed for ratification for the fiscal year ending December 31, 2026, with fees for 2025 and 2024 disclosed.

Next Steps

• Hold the 2026 Annual Meeting of Stockholders on April 28, 2026.
• Elect two Class I directors.
• Ratify the appointment of Baker Tilly US, LLP as the independent registered public accounting firm for fiscal year 2026.
• Management will report on performance and respond to stockholder questions during the meeting.
• Final voting results will be published in a Form 8-K within four business days of the meeting.

Key Dates

Recommendation

This filing is a routine proxy statement for an annual meeting and does not contain new material financial or strategic information that would warrant a buy or sell recommendation. It outlines standard governance procedures and director elections. Investors should refer to other filings for performance-based insights.

Keywords

Nuwellis, Proxy Statement, Annual Meeting, Director Election, Independent Auditor, Baker Tilly, Corporate Governance, Stockholder Vote, DEF 14A